Neuca S.A. (NEU)
Warsaw Stock Exchange · Poland · prices in PLN · close of 22 Oct 2026
Key indicators
| Last close | PLN 705.00 |
|---|---|
| 52-week range | 627.00 – 857.00 |
| Return, 1 month / 3 months | +2.9% / −5.6% |
| Return, 1 year / 3 years | −2.4% / +6.7% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 26.4% |
| Worst drawdown (1 year) | -22.9% |
| Average daily value traded | 3.87M PLN |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neuca is a Polish pharmaceutical wholesaler that distributes medicines, medical products and related goods to pharmacies and hospitals across the country. The company runs a network of distribution centres and logistics operations that supply independent and chain pharmacies, and it also provides services to pharmacies and operates its own retail pharmacy business. Neuca is based in Poland and serves the domestic healthcare market, working with drug manufacturers and healthcare providers.
The shares are listed on the Warsaw Stock Exchange in Poland under the code NEU, and the price on this page is in Polish zloty (PLN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Neuca S.A. (NEU) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 705.00 on 22 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 143 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 2.4% and over the last three months it fell 5.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -3.2% | ||
| From 52-week high | -17.1% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.6% | ||
| 6-month return | 4.6% | ||
| 12-month return, skipping the last month | -5.2% | ||
| Stability (higher is calmer) | 80 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.9% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 3.87M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.3% |
|---|---|
| 1 month | +2.9% |
| 3 months | −5.6% |
| 6 months | +4.6% |
| 1 year | −2.4% |
| 3 years | +6.7% |
| 5 years | −17.0% |
Signals
| 50-day / 200-day average | 737.14 / 727.94 |
|---|---|
| Golden / death cross (60 days) | Golden, 39 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 15.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jun 2026 | PLN 17.8000 |
| 15 Jul 2025 | PLN 16.0000 |
| 12 Jun 2024 | PLN 14.5000 |
| 17 Jul 2023 | PLN 13.0000 |
| 6 May 2022 | PLN 11.5000 |
| 10 May 2021 | PLN 10.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.